JP2023533111A - 免疫チェックポイント阻害剤とのstingアゴニスト併用治療 - Google Patents

免疫チェックポイント阻害剤とのstingアゴニスト併用治療 Download PDF

Info

Publication number
JP2023533111A
JP2023533111A JP2022568780A JP2022568780A JP2023533111A JP 2023533111 A JP2023533111 A JP 2023533111A JP 2022568780 A JP2022568780 A JP 2022568780A JP 2022568780 A JP2022568780 A JP 2022568780A JP 2023533111 A JP2023533111 A JP 2023533111A
Authority
JP
Japan
Prior art keywords
inhibitor
sting agonist
administered
ctla4
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533111A5 (cg-RX-API-DMAC10.html
Inventor
チェン、ジーチャン
サン、リージュン
Original Assignee
イミューンセンサー セラピューティクス、インコーポレイテッド
ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミューンセンサー セラピューティクス、インコーポレイテッド, ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム filed Critical イミューンセンサー セラピューティクス、インコーポレイテッド
Publication of JP2023533111A publication Critical patent/JP2023533111A/ja
Publication of JP2023533111A5 publication Critical patent/JP2023533111A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022568780A 2020-05-15 2021-05-17 免疫チェックポイント阻害剤とのstingアゴニスト併用治療 Pending JP2023533111A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063025905P 2020-05-15 2020-05-15
US63/025,905 2020-05-15
US202063091874P 2020-10-14 2020-10-14
US63/091,874 2020-10-14
PCT/US2021/032800 WO2021232019A1 (en) 2020-05-15 2021-05-17 Sting agonist combination treatments with immune checkpoint inhibitors

Publications (2)

Publication Number Publication Date
JP2023533111A true JP2023533111A (ja) 2023-08-02
JP2023533111A5 JP2023533111A5 (cg-RX-API-DMAC10.html) 2024-05-24

Family

ID=76306053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568780A Pending JP2023533111A (ja) 2020-05-15 2021-05-17 免疫チェックポイント阻害剤とのstingアゴニスト併用治療

Country Status (10)

Country Link
US (1) US20210380695A1 (cg-RX-API-DMAC10.html)
EP (1) EP4149457A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023533111A (cg-RX-API-DMAC10.html)
KR (1) KR20230011324A (cg-RX-API-DMAC10.html)
CN (1) CN115803032A (cg-RX-API-DMAC10.html)
AU (1) AU2021273508A1 (cg-RX-API-DMAC10.html)
CA (1) CA3178464A1 (cg-RX-API-DMAC10.html)
IL (1) IL298148A (cg-RX-API-DMAC10.html)
MX (1) MX2022014110A (cg-RX-API-DMAC10.html)
WO (1) WO2021232019A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114940679B (zh) * 2022-05-23 2023-05-16 浙江大学医学院附属第四医院 Sting激动剂前药化合物及其制备方法和应用
WO2024064724A1 (en) * 2022-09-21 2024-03-28 The University Of North Carolina At Chapel Hill Compositions and methods for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509339A (ja) * 2016-03-18 2019-04-04 イミューン センサー リミテッド ライアビリティ カンパニー 環状ジヌクレオチド化合物および使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CN103908468B (zh) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
DK3233882T3 (da) 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
EP4122492A1 (en) * 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
RU2019122598A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018118664A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
EP3755331B1 (en) 2018-02-21 2026-01-28 The Scripps Research Institute Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer
JP2023500045A (ja) * 2019-10-14 2023-01-04 イミューンセンサー セラピューティクス、インコーポレイテッド Stingアゴニストを用いたがんを処置する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509339A (ja) * 2016-03-18 2019-04-04 イミューン センサー リミテッド ライアビリティ カンパニー 環状ジヌクレオチド化合物および使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CASEY R. AGER ET AL.: ""Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immun", CANCER IMMUNOLOGY RESEARCH, vol. 5, no. 8, JPN6025021570, 2017, pages 676 - 684, ISSN: 0005734691 *
MAAIKE HENDRIKS ET AL.: ""Abstract 1702: Assessment of pharmacology and toxicology of anti-CTLA-4 antibody (ADU-1604) in non", CANCER RESEARCH, vol. Vol. 78, No. 13_Supplement, JPN6025021571, 2018, pages 1702, ISSN: 0005734690 *

Also Published As

Publication number Publication date
KR20230011324A (ko) 2023-01-20
IL298148A (en) 2023-01-01
MX2022014110A (es) 2023-01-30
EP4149457A1 (en) 2023-03-22
US20210380695A1 (en) 2021-12-09
AU2021273508A1 (en) 2022-12-15
WO2021232019A1 (en) 2021-11-18
CA3178464A1 (en) 2021-11-18
CN115803032A (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
CN104684579A (zh) 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
KR20230169462A (ko) Liv1-adc와 체크포인트 억제제를 사용한 병용 요법
Goldwasser et al. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients
JP2026503515A (ja) 非ホジキンリンパ腫治療用医薬組成物及びその使用
CN101669941A (zh) 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
US20210380695A1 (en) Sting agonist combination treatments with immune checkpoint inhibitors
US20230121320A1 (en) Sting agonist combination treatments with cytokines
JP2023500045A (ja) Stingアゴニストを用いたがんを処置する方法
HK40087098A (en) Sting agonist combination treatments with immune checkpoint inhibitors
CN120390655A (zh) 抗cd20抗体药物偶联物在制备治疗非霍奇金淋巴瘤的药物中的用途
US12240904B2 (en) Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors
HK40076423A (en) Methods of treating cancer with a sting agonist
Koukourakis et al. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer
EP4506015A1 (en) Combination of a mps1 inhibitor and an antibody drug conjugate
US20230218618A1 (en) Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies
JP2020172471A (ja) ヒト化抗ヒトcd26抗体を含有する医薬組成物
FUJISAWA et al. Immunotherapy for Pancreatic Cancer
WO2025261276A1 (zh) 含抗cd20抗体药物偶联物的药物组合及其治疗非霍奇金淋巴瘤的用途
JP2025505381A5 (cg-RX-API-DMAC10.html)
CN121969368A (zh) 治疗增殖性疾病如癌症的cxd101和il-15超激动剂的组合
IL316289A (en) Methods and compositions for treating diseases and disorders driven by eosinophils
EP1599210A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251119